These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 32521139)
1. Givosiran - Running RNA Interference to Fight Porphyria Attacks. Gonzalez-Aseguinolaza G N Engl J Med; 2020 Jun; 382(24):2366-2367. PubMed ID: 32521139 [No Abstract] [Full Text] [Related]
2. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L; N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132 [TBL] [Abstract][Full Text] [Related]
3. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693 [TBL] [Abstract][Full Text] [Related]
4. Givosiran for Acute Intermittent Porphyria. Gomá-Garcés E; Pérez-Gómez MV; Ortíz A N Engl J Med; 2020 Nov; 383(20):1989. PubMed ID: 33176091 [No Abstract] [Full Text] [Related]
5. [Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria]. Stölzel U Z Gastroenterol; 2020 Aug; 58(8):785. PubMed ID: 32785915 [No Abstract] [Full Text] [Related]
6. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran. de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921 [TBL] [Abstract][Full Text] [Related]
7. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. Sardh E; Harper P J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977 [TBL] [Abstract][Full Text] [Related]
12. Case report of a complicated neurologically manifesting acute porphyria treated successfully with Givosiran. Steinberg T; Kilic M; Fuchs K; Hanyk K; Linker RA; Schlachetzki F; Neumann B J Neurol Sci; 2021 Mar; 422():117334. PubMed ID: 33581419 [No Abstract] [Full Text] [Related]
13. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365 [TBL] [Abstract][Full Text] [Related]
14. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP). Massachi S; Epstein J; Hurd J; Bonkovsky HL J Med Econ; 2020 Dec; 23(12):1441-1449. PubMed ID: 33043761 [TBL] [Abstract][Full Text] [Related]
15. [New therapeutic option for acute hepatic porphyrias]. Stölzel U; Schuppan D Dtsch Med Wochenschr; 2021 Aug; 146(15):955-958. PubMed ID: 34344029 [TBL] [Abstract][Full Text] [Related]
16. Givosiran: First Approval. Scott LJ Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693 [TBL] [Abstract][Full Text] [Related]
17. Givosiran for Acute Intermittent Porphyria. Reply. Balwani M; Sardh E; Gouya L N Engl J Med; 2020 Nov; 383(20):1989-1990. PubMed ID: 33176092 [No Abstract] [Full Text] [Related]
18. Development of siRNA Therapeutics for the Treatment of Liver Diseases. Holm A; Løvendorf MB; Kauppinen S Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570 [TBL] [Abstract][Full Text] [Related]
19. Givosiran for the treatment of acute hepatic porphyria. Ricci A; Ventura P Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria. Agarwal S; Simon AR; Goel V; Habtemariam BA; Clausen VA; Kim JB; Robbie GJ Clin Pharmacol Ther; 2020 Jul; 108(1):63-72. PubMed ID: 31994716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]